Inovio Pharmaceuticals Reports Encouraging Results

Inovio Pharmaceuticals shares were barely higher Tuesday after the company said preliminary results from a phase I study of its Ebola DNA vaccine INO-4201 demonstrated that 95% of subjects generated an Ebola-specific antibody immune response, with the mean antibody titer comparable or superior to those reported from viral vector-based Ebola vaccines.

Inovio said the vaccine was well-tolerated with a favorable safety profile, compared to viral vector-based Ebola vaccines.

Leave a Comment